A NEW HIV PREVENTION STUDY FOR TEENSTHE HPTN 083-01 CLINICAL TRIAL for PrEP
HPTN 083-01 is a clinical trial examining whether injectable cabotegravir (CAB) for PrEP (Pre-Exposure Prophylaxis) is safe and acceptable for adolescent males [assigned male at birth – including transgender women (TGW), and gender nonconforming people]. This study will be enrolling about 50 participants at research centers in Boston, Chicago, and Memphis.
PrEP stands for Pre-Exposure Prophylaxis. PrEP is an HIV prevention strategy that uses anti-HIV medications to fight HIV in people who do not have HIV to reduce the risk of HIV. HPTN 083-01 is testing the safety and acceptability of long-acting injectable cabotegravir (CAB) for PrEP, which is not currently approved.
What will happen during HPTN 083-01?
- Step 1: Participants will take 1 CAB pill every day for 5 weeks
- Step 2: Participants will receive a total of 5 CAB injections over 6 months
- Step 3: Participants have the option to take oral PrEP or continue on injectable CAB LA for approximately a year.
These organizations are involved in this study: The National Institute of Allergy and Infectious Diseases (NIAID) is working with the HIV Prevention Trials Network (HPTN), The Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and ViiV Healthcare.
You can also learn more at inject2protect.org.
Complete the form today to see if your teen might qualify and to confidentially get in touch with your local research center.